Syncom Formulations (India) Limited (NSE:SYNCOMF)
17.49
+0.38 (2.22%)
Aug 19, 2025, 3:29 PM IST
NSE:SYNCOMF Revenue
Syncom Formulations (India) had revenue of 1.17B INR in the quarter ending June 30, 2025, with 33.98% growth. This brings the company's revenue in the last twelve months to 4.95B, up 70.10% year-over-year. In the fiscal year ending March 31, 2025, Syncom Formulations (India) had annual revenue of 4.65B with 76.55% growth.
Revenue (ttm)
4.95B
Revenue Growth
+70.10%
P/S Ratio
3.31
Revenue / Employee
4.96M
Employees
998
Market Cap
16.39B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 4.65B | 2.02B | 76.55% |
Mar 31, 2024 | 2.63B | 391.33M | 17.45% |
Mar 31, 2023 | 2.24B | 45.91M | 2.09% |
Mar 31, 2022 | 2.20B | -251.42M | -10.27% |
Mar 31, 2021 | 2.45B | 392.94M | 19.12% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |